Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Baxter
Express Scripts
McKinsey
Mallinckrodt

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR TAGRISSO


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Tagrisso

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02465060 ↗ Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting National Cancer Institute (NCI) Phase 2 2015-08-12 This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
NCT02496663 ↗ Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor Active, not recruiting National Cancer Institute (NCI) Phase 1 2016-03-24 This phase I trial studies the side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a better treatment for EGFR-mutant non-small cell lung cancer.
NCT02503722 ↗ Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer Active, not recruiting National Cancer Institute (NCI) Phase 1 2016-10-13 This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02520778 ↗ Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Active, not recruiting National Cancer Institute (NCI) Phase 1 2016-03-31 This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer that has spread to other places in the body (metastatic) or has not responded to previous treatment with initial EGFR kinase inhibitor. Osimertinib and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tagrisso

Condition Name

Condition Name for Tagrisso
Intervention Trials
Non-small Cell Lung Cancer 10
Stage IVA Lung Cancer AJCC v8 9
Stage IVB Lung Cancer AJCC v8 9
Stage IV Lung Cancer AJCC v8 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tagrisso
Intervention Trials
Carcinoma, Non-Small-Cell Lung 47
Lung Neoplasms 38
Carcinoma 17
Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tagrisso

Trials by Country

Trials by Country for Tagrisso
Location Trials
United States 262
Italy 21
Korea, Republic of 20
China 18
France 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tagrisso
Location Trials
California 20
Texas 14
Massachusetts 12
Ohio 12
New York 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tagrisso

Clinical Trial Phase

Clinical Trial Phase for Tagrisso
Clinical Trial Phase Trials
Phase 3 4
Phase 2 28
Phase 1/Phase 2 10
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tagrisso
Clinical Trial Phase Trials
Recruiting 28
Active, not recruiting 15
Not yet recruiting 12
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tagrisso

Sponsor Name

Sponsor Name for Tagrisso
Sponsor Trials
National Cancer Institute (NCI) 17
AstraZeneca 16
M.D. Anderson Cancer Center 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tagrisso
Sponsor Trials
Other 45
Industry 35
NIH 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Dow
Baxter
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.